Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

NASDAQ:LGND 4:00:00 PM EDT

102.94

+2.62 (+2.61%)

4:11:47 PM EDT: $103.20 +0.26 (+0.25%)

Market Cap (Intraday)	1.93B
Current PE	45.79
Forward PE	19.17
2yr Forward PE	16.66

See more stats

Estimates Current Quarter

Revenue	$38.97 Million
Adjusted EPS	$1.34

See more estimates

10-Day MA	$102.21
50-Day MA	$102.19
200-Day MA	$85.60

See more pivots

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B Stock, NASDAQ:LGND

555 Heritage Drive, Suite 200, Jupiter, Florida 33458

United States of America

Phone: +1.858.550.7500

Number of Employees: 58

http://www.ligand.com

Description

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.